Anti-Cdk6 antibody [8H4] (ab54576)
Key features and details
- Mouse monoclonal [8H4] to Cdk6
- Suitable for: WB
- Knockout validated
- Reacts with: Human
- Isotype: IgG1
Overview
-
Product name
Anti-Cdk6 antibody [8H4]
See all Cdk6 primary antibodies -
Description
Mouse monoclonal [8H4] to Cdk6 -
Host species
Mouse -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment: KDGLCRADQQ YECVAEIGEG AYGKVFKARD LKNGGRFVAL KRVRVQTGEE GMPLSTIREV AVLRHLETFE HPNVVRLFDV CTVSRTDRET KLTLVFE, corresponding to amino acids 3-100 of Human Cdk6
-
Positive control
- WB: HAP1, HeLa and Jurkat cell lysates.
-
General notes
This product was changed from ascites to tissue culture supernatant on 5th December 2019. Lot numbers higher than GR3279055 are from tissue culture supernatant. Please note that the dilutions may need to be adjusted accordingly. If you have any questions, please do not hesitate to contact our scientific support team.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
pH: 7.4 -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
8H4 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
KO cell lines
-
KO cell lysates
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab54576 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent concentration. Predicted molecular weight: 37 kDa.
|
Notes |
---|
WB
Use at an assay dependent concentration. Predicted molecular weight: 37 kDa. |
Target
-
Function
Probably involved in the control of the cell cycle. Interacts with D-type G1 cyclins. -
Sequence similarities
Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.
Contains 1 protein kinase domain. - Information by UniProt
-
Database links
- Entrez Gene: 1021 Human
- Omim: 603368 Human
- SwissProt: Q00534 Human
- Unigene: 119882 Human
-
Alternative names
- CDK 6 antibody
- CDK6 antibody
- CDK6_HUMAN antibody
see all
Images
-
All lanes : Anti-Cdk6 antibody [8H4] (ab54576)
Lane 1 : Wild-type HeLa cell lysate
Lane 2 : CDK6 knockout HeLa cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 37 kDa
Observed band size: 37 kDaLanes 1- 2: Merged signal (red and green). Green - ab54576 observed at 37 kDa. Red - Anti-alpha Tubulin antibody [EP1332Y] - Microtubule Marker (ab52866) observed at 50 kDa.
ab54576 was shown to react with Cdk6 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab266059 (knockout cell lysate ab257088) was used. Wild-type HeLa and CDK6 knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab54576 and Anti-alpha Tubulin antibody [EP1332Y] - Microtubule Marker (ab52866) overnight at 4°C at a 1 µg/ml and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye®800CW) preadsorbed (ab216772) and Goat Anti-Rabbit IgG H&L (IRDye®680RD) preadsorbed (ab216777) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
-
Lanes 1-2 : Anti-Cdk6 antibody [8H4] (ab54576) at 1 µg
Lanes 3-4 : Anti-beta Actin antibody (ab8227) at 1/2000 dilution
Lanes 1 & 3 : Wild-type HAP1 cell lysate
Lanes 2 & 4 : CDK6 knockout HAP1 cell lysate
Lysates/proteins at 20 µg per lane.
Predicted band size: 37 kDaLanes 1 and 2: Green signal from target – ab54576 observed at 37 kDa
Lanes 3 and 4: Red signal from loading control – ab8227 observed at 42 kDa
Lanes 5 and 6: Merged (red and green) signalab54576 was shown to react with CDK6 when CDK6 knockout samples were used, along with additional cross-reactive bands. Wild-type and CDK6 knockout samples were subjected to SDS-PAGE. ab54576 and ab8227 (loading control to beta actin) were diluted 1 µg/mL and 1/2000 respectively and incubated overnight at 4ºC. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) and Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.
This image was generated using the ascites version of the product.
-
Cdk6 antibody (ab54576) at 1ug/lane + Jurkat cell lysate at 25ug/lane.
This image was generated using the ascites version of the product.
Datasheets and documents
-
Datasheet download
References (14)
ab54576 has been referenced in 14 publications.
- Pessoa Rodrigues C & Akhtar A Differential H4K16ac levels ensure a balance between quiescence and activation in hematopoietic stem cells. Sci Adv 7:N/A (2021). PubMed: 34362741
- Ge JY et al. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun 11:2350 (2020). PubMed: 32393766
- Fassl A et al. Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Sci Adv 6:eabb2210 (2020). PubMed: 32704543
- Ding H et al. Linc00467 promotes lung adenocarcinoma proliferation via sponging miR-20b-5p to activate CCND1 expression. Onco Targets Ther 12:6733-6743 (2019). PubMed: 31686834
- Böhm MJ et al. Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib. Sarcoma 2019:3914232 (2019). PubMed: 30804704